We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

50 hedge funds and large institutions have $2.81M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

4% less funds holding

Funds holding: 52 → 50 (-2)

14% less capital invested

Capital invested by funds: $3.26M → $2.81M (-$458K)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
50
Holders Change
-2
Holders Change %
-3.85%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
13
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PPW
Pasadena Private Wealth
California
+$98.2K
2
RB
Richmond Brothers
Michigan
+$71.5K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$21.3K
4
Renaissance Technologies
Renaissance Technologies
New York
+$9.26K
5
TSS
Two Sigma Securities
New York
+$7.47K

Top Sellers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
-$203K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$12.4K
3
Corient Private Wealth
Corient Private Wealth
Florida
-$11.5K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$10.4K
5
IIA
IPG Investment Advisors
California
-$8.17K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$9.78K – – –
BWG
27
Beta Wealth Group
California
$9.6K – – –
AAM
28
Aureus Asset Management
Massachusetts
$9.06K – – –
WCA
29
Waypoint Capital Advisors
Minnesota
$7.88K -$4.22K -599 -31%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$6.79K +$1.3K +184 +20%
TSS
31
Two Sigma Securities
New York
$6.37K +$7.47K +1,061 New
JP Morgan Chase
32
JP Morgan Chase
New York
$6.09K +$7.06K +1,003 +100,300%
Mackenzie Financial
33
Mackenzie Financial
Ontario, Canada
$5.99K – – –
TRCT
34
Tower Research Capital (TRC)
New York
$5.8K -$3.48K -494 -34%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$5.28K – – –
UBS Group
36
UBS Group
Switzerland
$4.08K +$1.25K +178 +36%
Osaic Holdings
37
Osaic Holdings
Arizona
$3.73K +$352 +50 +9%
Jane Street
38
Jane Street
New York
$3.09K -$3.86K -548 -52%
NSIM
39
North Star Investment Management
Illinois
$3K +$1.76K +250 +100%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$3K +$3.07K +436 +681%
BBA
41
Baader Bank Aktiengesellschaft
Germany
$2.71K +$3.57K +507 New
Wells Fargo
42
Wells Fargo
California
$1.92K +$7 +1 +0.3%
Bank of America
43
Bank of America
North Carolina
$1.8K – – –
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$1.09K – – –
CCA
45
Column Capital Advisors
Indiana
$435 – – –
TC
46
Truvestments Capital
Florida
$132 – – –
LC
47
Lindbrook Capital
California
$90 – – –
SPIA
48
Steward Partners Investment Advisory
New York
$90 – – –
CAS
49
Coppell Advisory Solutions
Texas
$58 +$7 +1 +50%
NRG
50
Nemes Rush Group
Michigan
$22 – – –
1
2
3

ONCT Hedge Fund Activity: Q3 2023 in Review

50 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2023, worth a combined $2.81M — down 14% from $3.26M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ONCT and 3 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 13 added.

The largest buyer was Pasadena Private Wealth, opening a new position worth an estimated $98.2K. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $203K sold.

  • 50 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2023, down from 52 in Q2 2023.
  • Funds reported $2.81M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2023, down 14% quarter-over-quarter.
  • 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2023 and 5 closed out, a net change of -2 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2023 was Pasadena Private Wealth, an estimated $98.2K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2023 was Kennedy Capital Management, an estimated $203K sold.

Based on aggregated 13F filings for Q3 2023.